1. Introduction {#sec1-cells-08-01250}
===============

Breast cancer is the most prevalent type of cancer in women worldwide \[[@B1-cells-08-01250]\]. This makes it a cause of increasing concern, and it is important to address this issue. It was estimated that 41,070 breast cancer deaths occurred in women during 2017 in the USA alone, making it the second-leading cause of cancer-related death in women \[[@B1-cells-08-01250]\]. A large number of breast cancer patients are from developing countries as compared to Western countries, mainly due to their increasing populations \[[@B2-cells-08-01250]\]. In developed countries, breast cancer is often diagnosed early and treated accordingly; developing countries have higher death rates due to delayed diagnosis and improper access to healthcare \[[@B2-cells-08-01250]\]. Regardless of this, in developed countries breast cancer is second to lung cancer for cancer-related deaths in women \[[@B2-cells-08-01250]\]. Asia has 44% of the world's breast cancer deaths, with 39% of overall new breast cancer cases diagnosed \[[@B2-cells-08-01250]\]. In India, breast cancer has been ranked as the foremost cancer among the Indian female population \[[@B3-cells-08-01250]\]. Approximately 25% of female cancer cases in the country are breast cancer \[[@B4-cells-08-01250],[@B5-cells-08-01250]\]. The rate of incidence was found to be 25.8 in 100,000 women, and the mortality rate was 12.7 per 100,000 women (2017 statistics) \[[@B3-cells-08-01250]\]. The highest rate of incidence was found to be in Delhi (41 per 100,000 women) followed by Chennai (37.9 per 100,000 women), Bangalore (34.4 per 100,000 women) and Thiruvananthapuram district (33.7 per 100,000 women) \[[@B3-cells-08-01250]\]. When the mortality-to-incidence ratio was analysed, it was found to reach 66 in rural registries and 8 in urban registries \[[@B3-cells-08-01250]\]. Another troubling concern about the scenario of breast cancer in India is the increased incidence of disease in younger Indian women (between the ages of 30 and 40) \[[@B3-cells-08-01250],[@B4-cells-08-01250],[@B5-cells-08-01250]\]. Presently, almost 48% of breast cancer patients in India are below 50 years of age \[[@B4-cells-08-01250],[@B5-cells-08-01250]\]. There is an increasing trend of breast cancer in women between the ages of 25 to 40 in the past 25 years \[[@B4-cells-08-01250],[@B5-cells-08-01250]\].

At present, breast cancer is classified into four types: (1) Luminal A (classical hormone-positive tumours); (2) Luminal B (hormone-positive with higher ki 67 and poorer prognosis); (3) Triple-negative (ER/PR/HER neu negative); and (4) Her 2 neu overexpressing \[[@B6-cells-08-01250],[@B7-cells-08-01250]\]. Currently, several treatments are available for breast cancer, and these include: surgical resection \[[@B8-cells-08-01250]\], which is often followed by radiotherapy \[[@B9-cells-08-01250]\], hormone replacement therapy (differs in pre-menopausal and post-menopausal women) \[[@B10-cells-08-01250]\], targeted therapies \[[@B11-cells-08-01250]\], immunotherapy \[[@B12-cells-08-01250]\] and chemotherapeutic drugs \[[@B13-cells-08-01250]\]. There are a number of chemotherapeutic drugs that are commonly in use and have distinct mechanisms of action, such as anthracyclines (e.g., doxorubicin \[[@B14-cells-08-01250]\] and epirubicin \[[@B15-cells-08-01250]\]), taxanes (e.g., Paclitaxel \[[@B16-cells-08-01250],[@B17-cells-08-01250]\], docetaxel \[[@B16-cells-08-01250]\]), alkylating agents (e.g., cyclophosphamide (CTX) \[[@B18-cells-08-01250]\], carboplatin \[[@B17-cells-08-01250]\]), trastuzumab---a monoclonal antibody targeted against Her 2 neu \[[@B17-cells-08-01250]\], anti-metabolites (e.g., 5-fluorouracil (5-FU)) \[[@B18-cells-08-01250]\], and hormonal agents (e.g., tamoxifen, estradiol (E2), fulvestrant, anastrazole, letrozole).

Conventional chemotherapeutics for breast cancer treatment comprise cytotoxic \[[@B19-cells-08-01250]\], hormonal \[[@B20-cells-08-01250]\], and immunotherapeutic agents \[[@B21-cells-08-01250]\]. Both in neoadjuvant and adjuvant instances, the effectiveness of the chemotherapeutics is limited by resistance developed in the tumour tissue. This is mainly due to the various genetic and epigenetic changes found in cancer cells, and the resistance thus conferred may be intrinsic or acquired \[[@B22-cells-08-01250]\]. Like most other tumour cells, breast cancer cells exhibit the phenomenon of multi-drug resistance (MDR) \[[@B23-cells-08-01250]\]. MDR is characterized by a combination of mechanisms including, P-glycoprotein (P-gp) \[[@B20-cells-08-01250]\], multidrug-resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) of the ATP-binding cassette (ABC) membrane transporter family, which efflux a diverse range of anticancer drugs from the tumour cells \[[@B23-cells-08-01250],[@B24-cells-08-01250]\]. Other notable mechanisms that simultaneously contribute to MDR are enhanced aldehyde dehydrogenase (ALDH) activity, up-regulation of anti-apoptotic B-cell lymphoma-2 (Bcl-2) family proteins and abnormal activation of signalling pathways such as PI3K (phosphatidylinositol 3-kinase)/Akt, Notch, Hedgehog and Wnt pathways \[[@B25-cells-08-01250],[@B26-cells-08-01250],[@B27-cells-08-01250]\]. These mechanisms are predominantly showcased in CSCs (cancer stem cells).

The recent surge in the number of cancer cases along with the development of drug resistance in a large number of tumours has pushed the direction of cancer research towards new arenas that provide the grounds for the development of more effective personalised medicine treatment. MicroRNAs (miRNAs) pave the way for this by being potential biomarkers for early cancer detection, and could also help in designing a more specific treatment plan by helping in the analysis of drug resistance and sensitivity \[[@B28-cells-08-01250]\]. Various studies have been conducted highlighting the effect of miRNAs in chemotherapeutic resistance in cancers such as gastric cancer \[[@B29-cells-08-01250]\], breast cancer \[[@B30-cells-08-01250]\], cervical cancer \[[@B31-cells-08-01250]\], colorectal cancer \[[@B32-cells-08-01250]\], lung cancer \[[@B33-cells-08-01250]\], oral cancer \[[@B34-cells-08-01250]\], ovarian cancer \[[@B35-cells-08-01250]\], pancreatic cancer \[[@B36-cells-08-01250]\], prostate cancer \[[@B37-cells-08-01250]\] and skin cancer \[[@B38-cells-08-01250]\].

In one study it was found that there was increased resistance to docetaxel in breast cancer tissues having decreased expression of miR-638, and the restoration of miR-638 in these tissues led to apoptosis and enhanced sensitivity to docetaxel \[[@B39-cells-08-01250]\]. Microarray miRNA expression analysis in OHT (4-hydroxytamoxifen) showed the overexpression of eight miRNA genes, namely, miR-221, miR-222, miR-181, miR-203, miR-375, miR-32, miR-171, and miR-213, as compared to regular MCF-7 cell line conferring resistance \[[@B40-cells-08-01250]\]. Furthermore, seven miRNAs were under-expressed in OHT cells: miR-342, miR-484, miR-21, miR-24, miR-27, miR-23 and miR-200. miR-221 and miR-222 were also found to be up-regulated in HER2/neu-positive primary human breast cancer cells \[[@B40-cells-08-01250]\].

When an MCF7 (Michigan Cancer Foundation-7 cell line treated with VP-16 (etoposide) was compared with the untreated parent MCF7 cell line, it was observed that 17 miRNAs had abnormal levels of expression; the majority of them were up-regulated, whereas miR-326, miR-429, miR-187, miR-7, and miR-92-2 showed decreased expression \[[@B41-cells-08-01250]\]. The results were verified by RT-PCR, and it was concluded that these miRNAs could be specific regulators of MRP1 (multidrug-resistance-associated protein) and play a critical role in MDR (multiple drug resistance) \[[@B41-cells-08-01250]\].

A clinical study comparing the effects of the drug tamoxifen versus tamoxifen plus breast radiotherapy, carried out on 71 lymph-node-negative (LNN) breast cancer patients, revealed that the up-regulation of miRNA-301 in co-operation with SKA2 (spindle kinetochore-associated complex subunit 2) increased proliferation, migration, invasion and tumour formation through the regulation of key signalling pathways including PTEN, FOXF2 and Col2A1 \[[@B42-cells-08-01250]\]. According to another study, high levels of miRNA-210 expression in plasma was observed to be associated with trastuzumab resistance in HER-2 (human epidermal growth factor receptor 2)-positive breast cancer patients \[[@B43-cells-08-01250]\]. Xiang Ao and his colleagues examined 55 pairs of breast cancer tissues and adjacent normal tissues in total, and found that resistance to taxol in breast cancer patients increased with the loss of miRNA-17 and miRNA-20b, by the up-regulation of nuclear receptor co-activator 3 (NCOA3) levels \[[@B44-cells-08-01250]\].

Over the years, several studies have focused on the role of various miRNAs in the chemotherapeutic resistance or sensitivity in breast cancer. However, none of these studies have been able to conclusively define the exact mechanism by which these miRNAs are involved in chemo-sensitivity/resistance. Through this study, we aim to provide insight into the association of the expression of specific miRNAs with breast-cancer-related chemotherapeutic drug resistance and sensitivity, thereby making it relevant in a clinical setting. Further, this study paves the way to devise new treatment strategies targeting these miRNAs, and developing alternate ways to counter the occurrence of chemo-resistance in breast cancer. This study was carried out with the aid of tools including meta-analysis and systematic review.

2. Methods {#sec2-cells-08-01250}
==========

To obtain studies to perform the meta-analysis, two databases were extensively used: PubMed and Science Direct. This systematic review required articles related to the chemotherapeutic resistance specific to miRNA in breast cancer. To obtain relevant papers, the selection was performed using of the following MeSH (Medical Subject Heading) terms: "miRNA" or "microRNA", "drug resistance" and "breast cancer". To further refine the process of selection, only papers published within 2012--2018 were selected. This systematic review and meta-analysis study adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines \[[@B45-cells-08-01250]\].

The study search ended on (31 December 2018). After the initial screening process, additional studies were obtained via the reference section of relevant articles. The relevance of articles was determined by reading the title and abstract followed by the analysis of the complete text. The search was conducted in an orderly and elaborate manner, and was designed to meet the requirements of the study.

2.1. Selection Criteria {#sec2dot1-cells-08-01250}
-----------------------

Studies that were to be used in the systematic review and meta-analysis had to adhere to certain selection criteria. These criteria were of two types: inclusion criteria and exclusion criteria. The inclusion criteria set the guidelines for the studies that could be included in the analysis process and included the following factors:An analysis of the association between miRNA and breast cancer;Studies with both breast cancer patients as well as in vitro studies with cell lines;Studies that focused on cancer tissues that had resistance to some form of therapy;Reporting of miRNA profiling platforms;Information about the genes or pathways involved in chemotherapeutic resistance or sensitivity;Inclusion of some in vitro assays to analyse the expression of miRNA or gene-related studies.

Some studies were not considered because of certain exclusion criteria. These included studies that were not in the English language, did not involve drug resistance in breast cancer, studies involving microbes and those focusing only on long non-coding (lnc) RNA. Additionally, review articles, editorials and studies with only in vitro or only breast cancer patient samples were excluded.

2.2. Data Analysis {#sec2dot2-cells-08-01250}
------------------

The studies were evaluated separately by both authors (RJ and MRM), and further elaboration was performed with the help of corresponding authors. All articles were subject to the exclusion and inclusion criteria. An MS Excel worksheet (Master) was used to structurally store all the information obtained from the studies that qualified for final inclusion. After a complete survey of full-text and supplementary material, the data from all the studies were broken down under the following important headings: First author, Year of publication, Patients information, Location of the study, Ethnicity, Gender, Drug used, Clinical stages, Number of samples, Lymph node metastasis, Cell lines used, miRNA(s) involved, miRNA profiling platform and Drug pathways or gene associated. A number of biochemical and molecular assays were used to qualitatively and quantitatively analyse the miRNA expression in various studies. The frequency of their usage in all studies were compared and duly represented in a graphical form.

For further qualification of the studies, they had to pass a set of criteria that ensured a degree of quality control \[[@B46-cells-08-01250],[@B47-cells-08-01250],[@B48-cells-08-01250]\]. Two of the authors (RJ and MRM) critically assessed the quality of eligible articles for epidemiological studies based on some checklists derived from Dutch Cochrane Centre represented by Meta-analysis Of Observational Studies in Epidemiology (MOOSE) \[[@B49-cells-08-01250]\]. The studies that were finally selected had to meet all the criteria as determined by the authors. This process of sorting all the information obtained was a step that was crucial to ensure efficient examination of the studies.

2.3. Publication Bias {#sec2dot3-cells-08-01250}
---------------------

On the basis of a few distinct methods, two of the authors (RJ and MRM) individually assessed the risk of bias \[[@B50-cells-08-01250],[@B51-cells-08-01250],[@B52-cells-08-01250],[@B53-cells-08-01250],[@B54-cells-08-01250]\]. This included the number of patients, year of publication, study period, study location and diagnostic procedure. With the information obtained from the eligible studies, the reviewers arrived at a decision \[[@B55-cells-08-01250],[@B56-cells-08-01250],[@B57-cells-08-01250],[@B58-cells-08-01250],[@B59-cells-08-01250]\]. Egger's and Begg's bias indicator tests were employed to infer the publication bias along with the inverted funnel plot \[[@B60-cells-08-01250],[@B61-cells-08-01250],[@B62-cells-08-01250],[@B63-cells-08-01250]\]. The effect size of statistically non-significant, unpublished and small studies was addressed using classic \[[@B64-cells-08-01250]\] and Orwin \[[@B65-cells-08-01250]\] fail-safe N tests. Duval and Tweedie's trim and fill calculation was also performed to compute the new size effect, after the removal of an extremely positive and small study, until a symmetric funnel plot was obtained \[[@B66-cells-08-01250]\]. A third reviewer was consulted to resolve any disagreement regarding the decision of the team.

2.4. Statistical Analysis {#sec2dot4-cells-08-01250}
-------------------------

We used the Comprehensive Meta-Analysis (CMA) 3.0 software for the meta-analysis and calculated the hazard ratios (HRs) with 95% confidence intervals (CIs). Cochran's Q test and Higgins' I^2^ statistic \[[@B67-cells-08-01250]\] were used to obtain the heterogeneity, and statistical significance was defined as a *p-*value less than 0.01. A fixed-effect model \[[@B67-cells-08-01250]\] or random-effects model \[[@B68-cells-08-01250]\] was used to calculate 95% CI in cases where significant heterogeneity was not observed. The overall standard deviation (SD) of each sample from the main sample was calculated using the statistical Z-test.

3. Results {#sec3-cells-08-01250}
==========

The eligible studies for our systematic review and meta-analysis through search results identified are shown in the form of the flow chart in [Figure 1](#cells-08-01250-f001){ref-type="fig"}. Of the 4584 potential studies, 600 were screened for further proceeding and 92 articles were analysed in depth. Finally, 85 studies were found to be confined to the inclusion and exclusion criteria and the eligible studies involved 5159 tissues. The main characteristics of the patients are represented in [Table 1](#cells-08-01250-t001){ref-type="table"}. The systematically reviewed articles met all the criteria, and of the 85 articles included only 6 had hazard ratios and 95% confidence intervals and among these 3 articles denoted them directly in the article and 3 were extracted from Kaplan--Meier curves through online software. Between the 85 articles published, 57 were from China, 9 were from the USA, 5 were from Japan, 3 were from India, 2 each were from France, Italy and Taiwan, and there was 1 from each of Argentina, Canada, Finland, South Korea and Spain. Thirty studies used frozen tissues samples, 15 studies used formalin fixed paraffin embedded (FFPE) samples, 6 studies used core needle biopsy and 1 used blood sample. Meanwhile, 33 studies did not mention the type of material used.

A total of 22 cell lines were used in the 85 studies, and MCF-7, SKBR3, T47D and MDA-MB-231 cell lines were the most frequently included, with MCF-7 used in 33 studies. Zhao Y et al. (2011) used the highest number of cell lines in a single study \[[@B135-cells-08-01250]\].

Overall, 188 miRNAs were studied in our systematic review and meta-analysis, conjointly 96 miRNAs were upregulated and 87 miRNAs were downregulated. Elevated expression of miR- 18a, 21, 21-3p, 29a, 31, 34a, 34c-5p, 124, 125b, 130b, 137, 138, 138-5p, 139, 139-5p, 140, 140-3p, 141, 149, 149-3p, 155-5p, 181a-5p, 181b, 181b-5p, 181d, 183-5p, 197, 197-3p, 200a-5p, 200c, 205, 210, 210-3p, 221, 222, 378a-3p, 423, 423-5p, 520h, 574, 574-3p, 663, 671, 671-5p, 744, 744-5p, 944, 1246, 1268a, 3178, 3613, 3613-5p, 4258, 4298, 4438, 4443, 4644, 6780b, 6780b-3p, 7107, 7107-5p, 7847, 7847-3p, Let-7a and Lin28 and redundant expression of miR-7, 10b-5p, 17, 20a, 20b, 21, 24-2, 25, 25-3p, 27b, 31-5p, 34a-3p, 103, 125a-3p, 125, 125b-5p, 128, 134, 145, 148a, 149, 181a, 191, 195, 195-5p, 200c, 210, 221, 222, 301a, 320a, 375, 424, 451, 489, 520b-5p, 532-3p, 548n, 574-3p, 708-3p, 873 and Let7a were associated with chemotherapeutic resistance and increased expression of miR- 16, 27a, 34a, 128, 148a, 152, 155, 210, 221, 346, 484 and Let-7 and reduced expression of miR- 21, 24, 23b, 26a, 26b, 27b, 27b-3p, 34a, 100, 125a-3p, 125b-1, 130a-3p, 139, 145, 181a, 181b, 195, 200, 200c, 205, 214, 216b, 218, 301, 320a, 326, 342, 370, 378a-3p, 451a, 489, 576-3p, 638, 760, 765, 1254, Let-7 and Let-7a were associated with chemosensitivity.

Five miRNAs were differentially regulated and four miRNAs (i.e., miR- 90b, 130a, 200b and 452) contributed to chemoresistance. miR-491-3p did not have any impact on chemoresistance or sensitivity. Chemotherapeutic resistance and chemosensitivity were boosted by the miRNAs through drug-regulated cellular pathways. In total, 26 drugs were studied in the included articles: 5-FU, anastrozole, cisplatin, cyclophosphamide, docetaxel, doxorubicin, E2, epirubicin, etoposide, fulvestrant, gemcitabine, lapatinib, letrozole, methotrexate, mitoxantrone, Paclitaxel, PiB, tamoxifen, topotecan, trastuzumab, vinorelbine and combinations such as cisplatin plus doxorubicin, epirubicin plus Paclitaxel, Paclitaxel plus carboplatin, taxol plus doxorubicin plus Cyclophosphamide, Methotrexate, Fluorouracil (CMF), and anthracycline plus taxane were studied, and radiotherapy was also observed in one study.

miRNA Pathway Relation
----------------------

The miRNA and pathways involved in chemoresistance and chemosensitivity are represented in [Table 2](#cells-08-01250-t002){ref-type="table"} and [Table 3](#cells-08-01250-t003){ref-type="table"}, respectively.

The relationship between miRNA expression and patient survival was assessed by meta-analysis. Breast cancer (BC) patients had elevated expressions of miR-125b (HR = 6.350, 95% CI = 1.211--33.297), 484 (HR = 0.375, 95% CI = 0.193--0.730), 520h (HR = 1.233, 95% CI = 0.890--1.707), 4443 (HR = 0.721, 95% CI = 0.529--0.983) and downregulated expression of miR-200c (HR = 0.433, 95% CI = 0.102--1.829), 489 (HR = 0.703, 95% CI = 0.415--1.191). An extensive examination found that 89 out of 95 articles did not mention the HR and 95% confidence interval values and of the six remaining articles, only three mentioned them in their manuscript and three HR values were obtained from Kaplan--Meier curve through online software. So, 89 studies were excluded from our meta-analysis due to insufficient data. Cumulatively, a meta-analysis was done for six studies encompassing 852 samples ([Figure 2](#cells-08-01250-f002){ref-type="fig"}).

An unbiased correlation was observed from Begg and Mazumdar rank collection test results. Regarding Duval and Tweedie's trim and fill calculation for the fixed-effect model, the point estimate and 95% confidence interval for the combined studies was 0.83921 (0.69115--1.01899). Under the random-effects model, the point estimate and 95% confidence interval for the combined studies was 0.79909 (0.50575--1.26256). Using trim and fill, these values were unchanged. Egger's regression intercepted at −0.132 with 95% CI from −5.141 to 4.877; t = 0.07, *p* = 0.945. The 1-tailed *p*-value was 0.47237, and the 2-tailed *p*-value was 0.94473. The funnel plot is represented in [Figure 3](#cells-08-01250-f003){ref-type="fig"}.

4. Discussion {#sec4-cells-08-01250}
=============

This systematic meta-analysis of "the miRNAs that influence the chemoresistance or chemosensitivity to drugs in breast cancer" carefully reviewed over 400 research articles through a systematic PubMed search query from which 80 research articles were scrutinized based on the inclusion criteria.

From the meta-analysis, the results indicate that many miRNAs could intricately orchestrate cellular functions including chemosensitivity/resistance through post-transcriptional control on target gene expression, either canonically or non-canonically. Of the studies included in this meta-analysis, anthracyclines like doxorubicin and epirubicin were predominantly tested in patients/cell lines to study the differential expression of miRNAs followed by tamoxifen in the case of Estrogen Receptor (ER) positive subjects and trastuzumab in the case of Human Epidermal growth factor Receptor (HER) positive subjects. A major limitation in our research is that less than 10% of the 80 papers (6 papers) had direct hazard values that could be utilized for the meta-analysis, reducing the accuracy of the results obtained since only a small fraction of papers were used to give results of the whole, leading to the biasing of the results. There is a possibility of our interpretation being wrong in the context of heterogeneous disease.

4.1. Role of miRNAs in Guiding Diagnosis and Prognosis {#sec4dot1-cells-08-01250}
------------------------------------------------------

We extracted the prognosis results of six miRNAs from six different studies. Among the selected miRNAs, two miRNAs (miR200c and miR489) were downregulated and the remaining four miRNAs (miR484, miR4443, miR520h and miR125b) were upregulated. Both downregulated miRNAs were associated with better prognosis; similarly, both miRNAs (miR484 and miR4443) from the overexpressed miRNAs were expressed as better prognosis whereas miR520h and miR125b were associated with poor prognosis.

The overall hazard ratio (95% CI) of the prognostic significance was 0.78 (0.508--1.100) at a *p*-value of 0.140 which was analysed by random-effect model. This overall combined sized effect estimate indicates that the miRNAs decreased the likelihood of death of breast cancer patients by 22%. This means an HR value \>1 indicates an increased risk of breast cancer survival whereas an HR \<1 indicates a decreased risk of breast cancer patient survival. The Z-value of the overall effect size was −1.476. The individual overall hazard ratios (95% CIs) of upregulated and downregulated miRNAs were estimated 0.662 (0.403--1.087) and 0.904 (0.487--1.678), respectively. On observing the overall effect size of the individual subgroups, the significant prognosis was associated with a good prognosis, and hence the miRNAs could be considered as better prognostic biomarkers for breast cancer patients.

The Z-value of upregulated and downregulated miRNAs for the null hypothesis test (the mean risk ratio of which is 1.0) were −1.636 and −0.319, respectively. Both the differently expressed miRNA subgroups were associated with lower risk of death in breast cancer patients and hence we cannot accept the null hypothesis that the risk is lower in both differently expressed miRNAs. Similar to our study, two other studies have studied the subgroup analysis of higher and lower expressed miRNAs in meta-analysis studies of the prognosis of melanoma and nasopharyngeal carcinoma patient survival. Those studies demonstrated different risk levels among the subgroups, whereas in our study both subgroups exhibited better prognosis for cancer patients. More studies are required to obtain better prognostic significance of miRNAs in breast cancer patients \[[@B147-cells-08-01250]\].

4.2. Current Challenges {#sec4dot2-cells-08-01250}
-----------------------

Systematic reviews and meta-analytic studies face a number of challenges when investigating the theragnostic relationship between miRNA and chemotherapeutic response in breast cancer. The primary limiting factor for detailed analysis and clinically applicable insights/results is the scarcity of data. The literature in this specific niche of breast cancer treatment is sparse, with few high-quality studies being available for comparison and analysis. This challenge is exacerbated by the lack of homogeneity between similar studies. The variance in study parameters and the methodology makes assessment difficult by introducing uncertainty in the reliability of the results. Furthermore, a large number of studies have explored this topic via the use of in-vitro models, which cannot be directly applied to clinical theragnostics. The lack of well-documented, large-scale, patient-based clinical studies is a significant challenge faced by this study. Furthermore, the mechanisms of miRNA and chemotherapeutic response are not currently understood in detail, requiring further assessment in the future if meta-analytic studies are to provide conclusions viable for application in the clinical sphere.

The strengths of our paper include its large set of research papers, varied results in terms of miRNAs and pathways that show a change in function in cancerous cells. The result of this exhaustive analysis has provided us with a large number of miRNAs that can be focused on for prognostic or diagnostic purposes. Many miRNAs play a role in regulating many vital cellular pathways, and these regulations are observed to be significantly potentiated or deregulated during treatment with chemotherapeutics. A single miRNA can regulate multiple genes, and this regulation down the cascade can affect many pathways. Many reports have independently observed several genes or pathways as targets of many miRNAs. Of those, the treatment of doxorubicin has been frequently observed to affect the PTEN/Akt and MAPK signalling pathways, and increases chemoresistance ([Table 3](#cells-08-01250-t003){ref-type="table"}). In the case of miRNA 21 which is also an oncomiR, treatment with Fulvestrant; Selective Estrogen Receptor Degrader (SERD) or trastuzumab (HER2 antagonist) leads to downregulation, affecting the EMT. Whereas treatment with tamoxifen; Selective Estrogen Receptor Modulators (SERM) downregulates the expression of miRNA-21 via estrogen-dependent functions, leading to chemosensitivity.

In case of miRNAs 221 and 222, the treatment with fulvestrant, doxorubicin or trastuzumab also leads to the downregulation with increased expression of ABC transporters. The treatment with Paclitaxel leads to the downregulation of miRNA 320a with downregulation of TRPC5, NFATC3 and the FTS-1 genes, ultimately causing chemoresistance. miRNA 125b is upregulated when treated with tamoxifen, letrozole, anastrazole or fulvestrant due to its interaction with the Akt/mTOR pathway, leading to chemoresistance. The same pattern is observed when treatment of 5-FU, Paclitaxel and cyclophosphamide is applied, which affects the EMT pathway; or when 5-FU is used, which affects the transcription factor E2F3.

miRNAs Let-7, 181a and 145 are also majorly downregulated when treated with drugs like doxorubicin, tamoxifen, or epirubicin, with increases in chemosensitivity. Thus, myriad miRNAs take centre stage in the search for theragnostic miRNAs indicating drug resistance. However, Our study has tried its best to bridge the gaps, and serves as a benchmark for further clinical studies in personalized treatment research.
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cells-08-01250-t001_Table 1

###### 

Main characteristics of the included studies.

  Author                                                      Ethnicity (Patient)   Period of Study                         Drug(s)                                                                  Clinical Stages                                                                            No. of Samples (Cancer/Normal)   miRNA                                                                                                                                                    miRNA Profiling Platform
  ----------------------------------------------------------- --------------------- --------------------------------------- ------------------------------------------------------------------------ ---------------------------------- --------- --------- ----------------- ----------------- -------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lin X et al. (2017) \[[@B69-cells-08-01250]\]               Chinese               2001 to 2006 and 2015                   docetaxel                                                                2 stages (I--II and III)           74        4         60                0                 138/83                           34a                                                                                                                                                      GeneSpring GX (Agilent Technologies, Capital Biochip Corporation)
  Zhao G et al. (2017) \[[@B39-cells-08-01250]\]              Chinese               January 2012 to November 2015           docetaxel                                                                NM                                 NM        NM        NM                NM                78/78                            638                                                                                                                                                      qRT-PCR- SYBR Premix ExTaqTM (Takara, USA)
  Nakano M et al. (2017) \[[@B70-cells-08-01250]\]            Japanese              NM                                      methotrexate                                                             3 stages (I, I--II, II, II--III)   1         21        1                 NM                19/19                            25-3p and 125a-3p                                                                                                                                        Mx3000P (Stratagene, La Jolla, CA)
  Miao Y et al. (2017) \[[@B71-cells-08-01250]\]              Chinese               January 2014 to March 2016              doxorubicin                                                              NM                                 NM        NM        NM                NM                29/29                            130b                                                                                                                                                     SYBR Green qRT-PCR master mix (TaKaRa, Otsu, Shiga, Japan)
  Chen M-J et al. (2017) \[[@B72-cells-08-01250]\]            Taiwanese             NM                                      tamoxifen                                                                NM                                 NM        NM        NM                NM                36^a^                            148a, 152                                                                                                                                                ABI 7900 and SYBR® Select Master Mix (Applied Biosystems).
  Yang F et al. (2017) \[[@B73-cells-08-01250]\]              Chinese               2012--2015                              docetaxel                                                                NM                                 NM        NM        NM                NM                24/24                            346                                                                                                                                                      ABI 7300 real-time PCR machine (Applied Biosystems, USA)
  Gong J-P et al. (2016) \[[@B74-cells-08-01250]\]            Chinese               July 2010 to June 2014                  Paclitaxel                                                               NM                                 NM        NM        NM                NM                40^a^                            24                                                                                                                                                       TaqMan™ MicroRNA Assays (Applied Biosystems; Thermo Fisher Scientific, Inc.)
  Ao X et al. (2016) \[[@B44-cells-08-01250]\]                Chinese               2009--2011                              taxol                                                                    3 stages (II, III and III-IV)      0         12        18                25                55/55                            17 and 20b                                                                                                                                               SYBR on the CFX96 system (Bio-Rad).
  Zhu J et al. (2016) \[[@B75-cells-08-01250]\]               Chinese               2005--2009                              tamoxifen                                                                3 stages (II, III and III--IV)     0         8         22                22                73/19                            27b-3p                                                                                                                                                   SYBR on the CFX96 system (Bio-Rad)
  Chen X et al. (2016) \[[@B76-cells-08-01250]\]              Chinese               January 2010 to February 2015           docetaxel, epirubicin and vinorelbine                                    NM                                 NM        NM        NM                NM                55/26                            29a, 34a, 90b, 130a, 138, 139, 140, 149, 197, 200b, 210, 222, 423, 452, 574, 671, 744, 1246, 1268a, 3178, 3613, 4258, 4298, 4644, 6780b, 7107 and 7847   SYBR® Advantage® qPCR Premix, Light cycler system (Roche, Australia)
  Damiano V et al. \[[@B77-cells-08-01250]\]                  Italian               2000--2010                              anthracycline, anthracycline + taxane and CMF                            2 stages (I--II and III)           2                   48                0                 51^a^                            200c                                                                                                                                                     TaqMan normalizer (Applied Biosystems, ThermoFisher Scientific)
  Jana S et al. (2016) \[[@B78-cells-08-01250]\]              Indian                NM                                      NM                                                                       NM                                 NM        NM        NM                NM                35/35                            216b                                                                                                                                                     SYBR green detection system
  Wang D et al. (2016) \[[@B79-cells-08-01250]\]              Chinese               2010--2015                              doxorubicin                                                              NM                                 NM        NM        NM                NM                21^a^                            222                                                                                                                                                      SYBR Premix Ex Taq system (Roche, Australia)
  Xu X et al. (2016) \[[@B80-cells-08-01250]\]                NM                    2011--2014                              docetaxel                                                                NM                                 NM        NM        NM                NM                37/37                            125a-3p                                                                                                                                                  SYBR Premix ExTaqTM (Takara, USA)
  Chen X et al. (2016) \[[@B81-cells-08-01250]\]              Chinese               January 2010 to February 2015           epirubicin                                                               3 stages (I, II and III)           10        32        4                 0                 76^a^                            4443                                                                                                                                                     MiR-X miRNA qRT-PCR SYBR Kit (638314; Clontech Laboratories, USA)
  Gao M et al. (2016) \[[@B82-cells-08-01250]\]               Chinese               NM                                      doxorubicin                                                              NM                                 NM        NM        NM                NM                55/21                            145                                                                                                                                                      NCode VILO miRNA cDNA Synthesis Kit and the EXPRESS SYBR GreenER miRNA qRT-PCR Kit, respectively (Invitrogen, Carlsbad, CA, USA)
  Thakur S et al. (2016) \[[@B83-cells-08-01250]\]            Indian                NM                                      NM                                                                       2 stages (I--II and III--IV)       47                  38                                  100/100                          21, 145, 195, 210, 221 and Let-7a                                                                                                                        TaqMan Universal Master Mix kit (Applied Biosystems, USA)
  Hu Y et al. (2016) \[[@B84-cells-08-01250]\]                Chinese               June 2014 to June 2015                  docetaxel, doxorubicin and cyclophosphamide                              3 stages (II, III and III--IV)     0         7         19                4                 30^a^                            205                                                                                                                                                      TaqMan assays (Life Technologies)
  Sha L-Y et al. (2016) \[[@B85-cells-08-01250]\]             Chinese               NM                                      epirubicin plus Paclitaxel                                               NM                                 NM        NM        NM                NM                20/20                            18a                                                                                                                                                      TaqMan MicroRNA Assay Kit (Applied Biosystems)
  Chen X et al. (2016) \[[@B86-cells-08-01250]\]              Chinese               2008--2013                              doxorubicin                                                              4 stages (I, II, III and IV)       37        64        12                3                 114/114                          489                                                                                                                                                      SYBR Primescript miRNA RT PCR Kit (TaKaRa, Dalian, China)
  Venturutti L et al. (2016) \[[@B87-cells-08-01250]\]        Argentinians          2008--2014                              trastuzumab and lapatinib                                                4 stages (I, II, III and IV)       5         9         3                 2                 19^a^                            16                                                                                                                                                       TaqMan® MicroRNA assay (Ambion)
  Gu X et al. (2016) \[[@B88-cells-08-01250]\]                Chinese               January 2010 to December 2013           epirubicin and docetaxel                                                 2 stages (II and III)              NM        NM        NM                NM                82/60                            451                                                                                                                                                      miScript SYBR Green PCR Kit (QIAGEN, Hilden, Germany) and a real-time LightCycler PCR (Roche Molecular Biochemicals, Mannheim, Germany)
  Zhong S et al. (2016) \[[@B89-cells-08-01250]\]             Chinese               January 2010 to February 2015           docetaxel, epirubicin and vinorelbine                                    3 stages (I, II and III)           6         8         9                 0                 23^a^                            138-5p, 139-5p, 140-3p, 149-3p, 197-3p, 210-3p, 423-5p, 574-3p, 744-5p, 1246, 1268a, 3178, 4258, 4298, 4443, 4644, 6780b-3p, 7107-5p and 7847-3p         Affymetrix GeneChip miRNA 4.0 Array
  Zhang B et al. (2015) \[[@B90-cells-08-01250]\]             Chinese               NM                                      Paclitaxel                                                               NM                                 NM        NM        NM                NM                36/36                            100                                                                                                                                                      Realplex Real-time PCR Detection System (Eppendorf, Beijing, China)
  Shen R et al. (2015) \[[@B91-cells-08-01250]\]              Chinese               Between January 2006 to December 2011   tamoxifen                                                                NM                                 NM        NM        NM                NM                18^a^                            155                                                                                                                                                      SYBR Green PCR master mix (TaKaRa) on the ABI 7500HT System
  Yu X et al. (2015) \[[@B92-cells-08-01250]\]                Chinese               NM                                      tamoxifen and fulvestrant                                                NM                                 NM        NM        NM                NM                20/20                            214                                                                                                                                                      MiScript SYBR Green PCR kit (Qiagen)
  Zhou S et al. (2015) \[[@B93-cells-08-01250]\]              Chinese               March 2014 to June 2015                 cisplatin                                                                NM                                 NM        NM        NM                NM                40/40                            27a                                                                                                                                                      FastStart Universal STBR Green Master (Roche, Switzerland)
  Zheng Y et al. (2015) \[[@B94-cells-08-01250]\]             Chinese               NM                                      doxorubicin                                                              NM                                 NM        NM        NM                NM                30/30                            181b                                                                                                                                                     TaqMan MicroRNA assays kit (Applied Biosystems, USA)
  Ye Z et al. (2015) \[[@B95-cells-08-01250]\]                Chinese               NM                                      cisplatin                                                                NM                                 NM        NM        NM                NM                85/85                            221                                                                                                                                                      SYBR Green (Takara)
  Mattos-Arruda L-D et al. (2015) \[[@B96-cells-08-01250]\]   Spaniards             2005--2011                              trastuzumab, anthracyclines, taxanes                                     NM                                 NM        NM        NM                NM                85^a^                            21                                                                                                                                                       LightCycler 480 Real-Time PCR System (Roche)
  Lu L et al. (2015) \[[@B97-cells-08-01250]\]                Chinese               Not mentioned                           doxorubicin, cyclophosphamide and fluorouracil                           2 stages (II--III)                 NM        NM        NM                NM                40^a^                            134                                                                                                                                                      SYBR PrimeScript miRNA RT-PCR Kit (Takara, Japan)
  Zhang H-d et al. (2015) \[[@B98-cells-08-01250]\]           Chinese               2012--2015                              docetaxel                                                                2 stages (I--II and III)           18                  17                0                 35^a^                            139                                                                                                                                                      TaqMan MicroRNA Assay Kit (assay ID: miR-139-5p: 002289, and RNU6B: 001093), (Applied Biosystems, Life Technologies)
  He H et al. (2015) \[[@B99-cells-08-01250]\]                Chinese               October 2012 to January 2015            cisplatin                                                                NM                                 NM        NM        NM                NM                70/70                            944                                                                                                                                                      ABI PRISM 7900 Sequence Detection System (Applied Biosystems) with SYBR Green (TaKaRa, Japan)
  Ikeda K et al. (2015) \[[@B100-cells-08-01250]\]            Japanese              Not mentioned                           tamoxifen                                                                NM                                 NM        NM        NM                NM                40/16                            378a-3p                                                                                                                                                  TaqMan microRNA assays (Applied Biosystems, CA, USA)
  Wu J et al. (2015) \[[@B101-cells-08-01250]\]               Chinese               January 2005 to December 2006           before therapy                                                           NM                                 NM        NM        NM                NM                39^a^                            Let7a                                                                                                                                                    Real-time quantitative reverse transcription PCR (qRT-PCR)
  January 2008 to December 2009                               epirubicin            NM                                      NM                                                                       NM                                 NM        NM        31^a^                                                                                                                                                                                                                         
  Takahashi R et al. (2015) \[[@B102-cells-08-01250]\]        Japanese              1996--2000                              docetaxel                                                                1 stage (II--III)                  NM        26                          NM                26/9                             27b                                                                                                                                                      TaqMan MicroRNA Assays (Applied Biosystems)
  Niu J et al. (2015) \[[@B103-cells-08-01250]\]              Chinese               1 January 2009 to 31 December 2010      doxorubicin                                                              2 stages (I--II and III--IV)       49                  13                                  62^a^                            181a                                                                                                                                                     MyiQ Real-Time PCR Detection System (Bio-Rad)
  Su C-M et al. (2015) \[[@B104-cells-08-01250]\]             Taiwanese             NM                                      Paclitaxel                                                               2 stages (I and I--II)             36        110       NM                NM                146^a^                           520h                                                                                                                                                     Applied Biosystems 7900 Fast Real-Time PCR
  Boulbes D et al. (2015) \[[@B105-cells-08-01250]\]          American              NM                                      trastuzumab, fluorouracil, epirubicin and cyclophosphamide               NM                                 NM        NM        NM                NM                50^a^                            has-520b-5p, 532-3p, 548n and 34a-3p                                                                                                                     miRNA microarray (version 4.0, microRNACHIPv4)
  Manvati S et al. (2015) \[[@B106-cells-08-01250]\]          Indian                NM                                      docetaxel                                                                3 stages (I, II and III)           NM        NM        NM                NM                46/46                            24-2                                                                                                                                                     TaqMan microRNA assays (Applied Biosystems)
  Kang L et al. (2015) \[[@B107-cells-08-01250]\]             Chinese               NM                                      Paclitaxel                                                               4 stages (I, II, III and IV)       11        18        12                4                 45^a^                            34a                                                                                                                                                      TaqMan MicroRNA Assay kit (Applied Biosystems, Foster City, CA, USA)
  Lu M et al. (2015) \[[@B108-cells-08-01250]\]               Chinese               2009--2010                              tamoxifen                                                                NM                                 NM        NM        NM                NM                31/27                            320a                                                                                                                                                     Applied Biosystems Step One real-time PCR system using an SYBR Premix Ex Taq II Kit (Takara Bio, Inc., Shiga, Japan)
  Ye F-G et al. (2015) \[[@B109-cells-08-01250]\]             Chinese               September 2013                          gemcitabine                                                              3 stages (I, II and III)           159                 32                NM                400/243                          484                                                                                                                                                      SYBR Premix Ex Taq System (TaKaRa)
  Vilquin P et al. (2015) \[[@B110-cells-08-01250]\]          French                NM                                      letrozole, anastrazole, tamoxifen and fulvestrant                        3 stages (I, II and III)           4         18        23                0                 65/65                            125b                                                                                                                                                     ExiLENT SYBR Green Master Mix and CFX96 (BioRad, Marne-laCoquette, France)
  Ujihira T et al. (2015) \[[@B111-cells-08-01250]\]          Japanese              NM                                      tamoxifen                                                                NM                                 NM        NM        NM                NM                19^a^                            574-3p                                                                                                                                                   triplicate TaqMan microRNA assays (Applied Biosystems, CA, USA)
  Cui J et al. (2014) \[[@B112-cells-08-01250]\]              Chinese               NM                                      tamoxifen                                                                NM                                 NM        NM        NM                NM                NM                               873                                                                                                                                                      RNeasy Mini kit (Qiagen, Hilden, Germany) or TRIzol (Invitrogen) reagent. SYBR Green PCR Master Mix reagents using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA)
  Lv J et al. (2014) \[[@B113-cells-08-01250]\]               Chinese               2008--2009                              doxorubicin                                                              NM                                 NM        NM        NM                NM                NM                               31, 125b-1, 141, 145, 196b, 200a, 200c, 370, 429, 491-3p, 576, 760, 765 and Let-7a                                                                       ABI 7900 PCR System (Applied Biosystems, USA) using Power SYBR Green PCR Master Mix (2X, Applied Biosystems)
  He X et al. (2014) \[[@B114-cells-08-01250]\]               Chinese               NM                                      cisplatin                                                                4 stages (I, II, III and IV)       15 + 17   15 + 17   30 + 23           30 + 23           85^a^                            218                                                                                                                                                      TRIzol reagent (Invitrogen) miRNA microarray chip (v.10.0, Exiqon, Vedbaek, Denmark)
  Winsel S et al. (2014) \[[@B115-cells-08-01250]\]           Norwegians            May 1995 to December 1998               taxol                                                                    NM                                 NM        NM        NM                NM                101^a^                           378a-3p                                                                                                                                                  RNeasy Mini Kit (Qiagen) TaqMan Universal Master Mix II, no PNG (Applied Biosystems, Foster City, CA, USA)
  Hu J et al. (2014) \[[@B116-cells-08-01250]\]               Chinese               NM                                      NM                                                                       4 stages (I, II, III and IV)       20        25        31                4                 119^a^                           93                                                                                                                                                       TRIzol Reagent (Invitrogen) and the miRNeasy Mini Kit (QIAGEN)
  He DX et al. (2014) \[[@B117-cells-08-01250]\]              Chinese               NM                                      doxorubicin, Paclitaxel                                                  NM                                 NM        NM        NM                NM                NM                               320a                                                                                                                                                     All-in-One miRNA qRT-PCR detection kit (GeneCopoeia, Rockville, MD, USA)
  He DX et al. (2014) \[[@B118-cells-08-01250]\]              Chinese               NM                                      doxorubicin, Paclitaxel                                                  NM                                 NM        NM        NM                NM                NM                               149                                                                                                                                                      All-in-One miRNA qRT-PCR detection kit (GeneCopoeia, Rockville, MD, USA). Briefly, total RNA was extracted from MCF-7/WT and ADM cells with TRIzol (Invitrogen, Carlsbad, CA, USA)
  Ouyang M et al. (2014) \[[@B119-cells-08-01250]\]           Chinese               2011 (January--October)                 doxorubicin                                                              NM                                 NM        NM        NM                NM                NM                               10b-5p, 21-3p, 31-5p, 125b-3p, 130a-3p, 155-5p, 181a-5p, 181b-5p, 183-5p, 195-5p and 451a                                                                Total RNA was harvested using TRIzol (Invitrogen) and miRNAeasy mini kit (QIAGEN). SYBR Premix EX TaqTM II kit (Takara, Dalian, China)
  Luo ML et al. (2014) \[[@B120-cells-08-01250]\]             Chinese               NM                                      PiB                                                                      NM                                 NM        NM        NM                NM                NM                               200                                                                                                                                                      Total RNA was isolated from miRNeasy kit (Qiagen) and reversely transcribed by miScript PCR starter kit
  Jiang L et al. (2014) \[[@B121-cells-08-01250]\]            Chinese               NM                                      doxorubicin                                                              NM                                 NM        NM        NM                NM                NM                               489                                                                                                                                                      Total RNA was prepared using TRIzol (Beyotime, China) according to the manufacturer's instructions.
  Ye XM et al. (2014) \[[@B122-cells-08-01250]\]              Chinese               NM                                      trastuzumab/Herceptin                                                    NM                                 NM        NM        NM                NM                NM                               375                                                                                                                                                      Total RNA was extracted from each cell line using TRIzol reagent (Invitrogen, USA)
  Zhu Y et al. (2013) \[[@B123-cells-08-01250]\]              Chinese               NM                                      doxorubicin                                                              2 stages (I and II)                34        9         NM                NM                43^a^                            181a                                                                                                                                                     Total RNA was extracted from each cell line using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
  Ye X et al. (2014) \[[@B122-cells-08-01250]\]               Chinese               NM                                      trastuzumab                                                              NM                                 NM        NM        NM                NM                NM                               221                                                                                                                                                      Total RNA from each cell line was extracted by TRIzol reagent (Invitrogen, USA)
  Yang G et al. (2013) \[[@B124-cells-08-01250]\]             Chinese               NM                                      doxorubicin                                                              2 stages (I and II)                9         8         NM                NM                30^a^                            195                                                                                                                                                      Total cellular RNA from tissues and cultured cells were isolated using a TRIzol Reagent (Invitrogen)
  Pichiorri F et al. (2013) \[[@B125-cells-08-01250]\]        Americans             NM                                      fulvestrant                                                              NM                                 NM        NM        NM                NM                183/57                           21, 103, 221 and 222                                                                                                                                     TaqMan PCR kit (Applied Biosystems) and 7900HT Sequence Detection System (Applied Biosystems)
  Wang H-J et al. (2013) \[[@B126-cells-08-01250]\]           Chinese               January 2010 to December 2011           Paclitaxel, 5-FU, epirubicin and cyclophosphamide                        NM                                 NM        NM        NM                NM                19/19                            125b                                                                                                                                                     ABI 7900HT system (Applied Biosystems)
  Ji S et al. (2013) \[[@B127-cells-08-01250]\]               Chinese               2007--2009                              taxol + doxorubicin + cyclophosphamide                                   NM                                 NM        NM        NM                NM                67/67                            128                                                                                                                                                      QRT-PCR
  Hu H et al. (2013) \[[@B128-cells-08-01250]\]               Chinese               October 2003 to July 2010               topotecan, etoposide, doxorubicin, docetaxel and cyclophosphamide        NM                                 NM        NM        NM                NM                39/39                            663                                                                                                                                                      Conventional TaqMan PCR (Bio-Rad)
  Masuda M et al. (2011) \[[@B129-cells-08-01250]\]           Japanese              NM                                      estradiol (E2)                                                           NM                                 NM        NM        NM                NM                41^a^                            7                                                                                                                                                        PCR was performed in ABI7500 Real-Time PCR System (Applied Biosystems, Foster city, CA, USA)
  Li X et al. (2012) \[[@B130-cells-08-01250]\]               Chinese               2008--2010                              doxorubicin, cyclophosphamide (CTX) and 5-fluorouracil (5-FU)            1 stage (II)                       0         38        0                 0                 38/38                            34a                                                                                                                                                      SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA)
  Lv K et al. (2012) \[[@B131-cells-08-01250]\]               Chinese               2002--2010                              Paclitaxel, vincristine                                                  NM                                 NM        NM        NM                NM                9/9                              Lin28                                                                                                                                                    Real-time PCR was performed using the TaqMan MicroRNA Reverse Transcription Kit and the Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA)
  Wang H et al. (2012) \[[@B132-cells-08-01250]\]             Chinese               2009--2010                              5-FU (5-fluorouracil)                                                    2 stages (II and III)              0         35        21                0                 56/10                            10b, 34a, 125b and 155                                                                                                                                   miRNA-specific TaqMan MicroRNA Assays (Applied Biosystems)
  Jung E-J et al. (2012) \[[@B43-cells-08-01250]\]            Americans, Koreans    NM                                      trastuzumab, Paclitaxel, fluorouracil, cyclophosphamide and epirubicin   3 stages (I, II and III)           33        31        8                 0                 72/72                            21, 29a, 126 and 210                                                                                                                                     TaqMan MicroRNA Assay kit (Applied Biosystems, Foster City, Calif)
  Chen J et al. (2011) \[[@B133-cells-08-01250]\]             Chinese               2007--2011                              doxorubicin                                                              NM                                 NM        NM        NM                NM                39^a^                            200c                                                                                                                                                     Real-time PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, USA) on the Stepone plus system (Applied Biosystems, USA)
  Zhu Y et al. (2011) \[[@B134-cells-08-01250]\]              Chinese               2004--2011                              NM                                                                       3 stages (II, III and IV)          NM        44        29                4                 77^a^                            128                                                                                                                                                      Mature miRNA expression analysis was conducted using a TaqMan MicroRNA Assays (Applied Biosystems)
  Zhao Y et al. (2011) \[[@B135-cells-08-01250]\]             NM                    NM                                      tamoxifen                                                                NM                                 NM        NM        NM                NM                29/15                            Let-7                                                                                                                                                    mirVana miRNA isolation kit (Ambion Inc., Austin, TX, USA) or from FFPE tissues using the miRNeasy FFPE Kit (Qiagen, Valencia, CA, USA)
  Gong C et al. (2011) \[[@B136-cells-08-01250]\]             Chinese               2008--2009                              trastuzumab (Herceptin)                                                  NM                                 NM        NM        NM                NM                32^a^                            21                                                                                                                                                       Total RNA was harvested using TRIzol (Invitrogen) and the RNeasy minikit (Qiagen) according to the manufacturer's instructions.
  Shi W et al. (2011) \[[@B42-cells-08-01250]\]               NM                    NM                                      NM                                                                       3 stages (I, II and III)           8         33        30                NM                71^a^                            301                                                                                                                                                      Standard TaqMan MicroRNA Assay (Applied Biosystems)
  Cittelly D et al. (2010) \[[@B137-cells-08-01250]\]         Americans             1978--1993                              tamoxifen                                                                3 stages (I, II and III)           72        346       322               NM                791^a^                           342                                                                                                                                                      miRVANA RNA Isolation System (Ambion)
  Liang Z et al. (2010) \[[@B41-cells-08-01250]\]             Americans             NM                                      VP-16, mitoxantrone                                                      3 stages (I, III and IV)           5         NM        10 (III and IV)   10 (III and IV)   35^a^                            326                                                                                                                                                      Total RNA was extracted from 70% to 85% confluence of MCF-7 and MCF-7/VP cells with TRIzol (Invitrogen, Carlsbad, CA, USA)
  Maillot G et al. (2009) \[[@B138-cells-08-01250]\]          NM                    NM                                      tamoxifen                                                                2 stages (III and IV)              NM        NM        5                 10                15^a^                            21, 23b, 26a, 26b, 27b, 181a, 181b and 200c                                                                                                              miRNA microarray analysis was performed as described by Castoldi and colleagues
  Iorio M et al. (2009) \[[@B139-cells-08-01250]\]            Italians              NM                                      NM                                                                       NM                                 NM        NM        NM                NM                NM                               205                                                                                                                                                      TaqMan MicroRNA Reverse Transcription kit and TaqMan MicroRNA Assay were used to detect and quantify mature microRNA-205 (Applied Biosystems)
  Miller T et al. (2008) \[[@B40-cells-08-01250]\]            Americans             NM                                      tamoxifen                                                                NM                                 NM        NM        NM                NM                76^a^                            221 and 222                                                                                                                                              The miRNA microarray was performed at the Ohio State University Comprehensive Cancer Center Microarray Core Facility
  Yu F et al. (2007) \[[@B140-cells-08-01250]\]               Chinese               NM                                      epirubicin                                                               NM                                 NM        NM        NM                NM                25^a^                            Let-7                                                                                                                                                    NM
  Li G et al. (2016) \[[@B141-cells-08-01250]\]               Chinese               2001--2002                              tamoxifen                                                                NM                                 NM        NM        NM                NM                57/57                            1254                                                                                                                                                     mirVana miRNA isolation kit (Ambion) using stem-loop RT primers and analysed by qPCR (TaqMan, TaKaRa)
  Yu S-J et al. (2018) \[[@B142-cells-08-01250]\]             Chinese               2003--2009                              Paclitaxel and carboplatin                                               2 stages (II and III)              NM        28        44                NM                110/110                          200a-5p                                                                                                                                                  7900HT Fast Real-Time PCR System (Applied Biosystems)
  Lee J-W et al. (2017) \[[@B143-cells-08-01250]\]            South Korean          NM                                      doxorubicin                                                              2 stages (I--II and III--IV)       28        NM        21                NM                50/50                            708-3p                                                                                                                                                   High-Capacity cDNA Reverse Transcription Kit (Life Technologies)
  Si W et al. (2018) \[[@B144-cells-08-01250]\]               Chinese               NM                                      Paclitaxel                                                               3 stages (I, II and III)           15        38        53                0                 106/106                          20a                                                                                                                                                      SYBR Premix Ex Taq (TaKaRa, RR420A)
  Cheng S et al. (2018) \[[@B145-cells-08-01250]\]            Chinese               NM                                      cisplatin and doxorubicin                                                NM                                 NM        NM        NM                NM                57/31                            137                                                                                                                                                      ABI Prism 7900HT thermal cycler (Applied Biosystems, Foster City, CA, USA)
  Hu G et al. (2018) \[[@B146-cells-08-01250]\]               Chinese               August 2013 to December 2015            doxorubicin                                                              NM                                 NM        NM        NM                NM                30^a^                            125b                                                                                                                                                     ABI PRISM 7900 Sequence Detection system (Applied Biosystems)

NM: Not Mentioned; a: only cancer tissue; CMF: Cyclophosphamide, Methotrexate, Fluorouracil.
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###### 

Pathways involved in chemoresistance.

  Downregulated            Upregulated                                                                                        
  ------------------------ ------------- --------------------------------------------- ---------------------------- --------- ---------------------------------------------------------------------------------------------------
  5-FU                     134           ABCC1                                         5-FU                         125b      EMT
  anastrozole              424           Akt/mTOR pathway                              5-FU                         125b      Transcription factor E2F3
  anthracycline            200c          ZEB1                                          anthracycline                21        IL-6/STAT3/NF-κB/PI3K pathway.
  anthracycline + taxane   200c          ZEB1                                          cisplatin                    944       Bcl2/BNIP3
  CMF                      200c          ZEB1                                          cisplatin and doxorubicin    137       FSTL1/integrin β3/Wnt
  CTX                      134           ABCC1                                         CTX                          125b      EMT
  docetaxel                451           NM                                            CTX                          663       HSPG2
  docetaxel                24-2          YWHAZ, TP53, SMAD3, ESR1 and CREBBP           docetaxel                    663       HSPG2
  doxorubicin              145           MRP1                                          doxorubicin                  130b      PTEN/PI3K/Akt
  doxorubicin              320a          TRPC5, NFATC3 and ETS-1 gene                  doxorubicin                  222       PTEN/Akt/cyclin-dependent kinase (p27) pathway
  doxorubicin              149           GlcNAc-NDST1                                  doxorubicin                  181b      MMP/caspase pathway
  doxorubicin              103           NCL                                           doxorubicin                  663       HSPG2
  doxorubicin              222           NCL                                           doxorubicin                  31        MAPK signalling pathway, cytokine--cytokine receptor interaction
  doxorubicin              134           ABCC1                                         doxorubicin                  141       MAPK signalling pathway, cytokine--cytokine receptor interaction
  doxorubicin              181a          STAT3/NF-kB/MSK1                              doxorubicin                  200c      MAPK signalling pathway, cytokine--cytokine receptor interaction
  doxorubicin              10b-5p        PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes   doxorubicin                  181b-5p   PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes
  doxorubicin              125b-3p       PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes   doxorubicin                  183-5p    PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes
  doxorubicin              155-5p        PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes   doxorubicin                  195-5p    PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes
  doxorubicin              181a-5p       PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes   doxorubicin                  21-3p     PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes
  doxorubicin              31-5p         PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes   E2                           124       EGFR
  doxorubicin              200c          MDR1 mRNA                                     E2                           29a       EGFR
  doxorubicin              708-3p        ZEB1/CDH2/vimentin                            E2                           21        EGFR
  doxorubicin              125b          HAX-1                                         E2                           181d      EGFR
  E2                       301a          EGFR                                          E2                           34c-5p    EGFR
  E2                       20a           EGFR                                          epirubicin                   4443      TIMP2
  E2                       149           EGFR                                          epirubicin + Paclitaxel      18a       Dicer
  E2                       17            EGFR                                          epirubicin                   125b      EMT
  E2                       25            EGFR                                          etoposide                    663       HSPG2
  E2                       191           EGFR                                          fulvestrant                  125b      Akt/mTOR pathway
  E2                       27b           EGFR                                          letrozole                    205       Akt/mTOR pathway
  E2                       148a          EGFR                                          Paclitaxel                   520h      DAPK2
  E2                       210           EGFR                                          Paclitaxel                   Lin28     p21, RB, cyclin B1, Akt and Let-7 miRNA
  E2                       7             EGFR                                          Paclitaxel                   125b      EMT
  epirubicin               Let7a         H-RAS/HMGA2                                   Paclitaxel and carboplatin   200a-5p   TP53INP1/YAP1
  epirubicin               Let7a         H-RAS/HMGA2                                   tamoxifen                    222       p27Kip1
  epirubicin               451           NM                                            tamoxifen                    221       p27Kip1
  fulvestrant              21            NCL                                           taxanes                      21        IL-6/STAT3/NF-κB/PI3K pathway
  methotrexate             25-3p         ADAR1/DHFR                                    taxol                        378a-3p   Triggered receptor tyrosine kinase--MAP kinase pathway signalling, suppression of Aurora B kinase
  methotrexate             125a-3p       ADAR1/DHFR                                    topotecan                    663       HSPG2
  Paclitaxel               320a          TRPC5 gene; NFATC3gene; ETS-1 gene            trastuzumab                  21        IL-6/STAT3/NF-κB/PI3K pathway
  Paclitaxel               149           GlcNAc-NDST1                                  trastuzumab                  221       PTEN
  Paclitaxel               20a           MAPK1/c-Myc                                   trastuzumab                  21        PTEN
  tamoxifen                574-3p        CLTC                                          vincristine                  Lin28     p21, RB, cyclin B1
  tamoxifen                873           CDK3, Erα                                                                            
  tamoxifen                424           Akt/mTOR pathway                                                                     
  taxol                    17            NCOA3                                                                                
  taxol                    20b           NCOA3                                                                                
  trastuzumab              221           NCL                                                                                  
  trastuzumab              375           IGF1R                                                                                

anthracyclin: epirubicin/doxorubicin; EMT: Epithelial-Mesenchymal Transition.
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###### 

Pathways involved in chemosensitivity.

  Downregulation   Upregulation                                                                                                                       
  ---------------- -------------- ------------------------------------------------------------------ ---------------------------------------- ------- ------------------------------------------------------------------
  CTX              205            VEGF/FGF2                                                          5-FU                                     34a     Notch 1
  cisplatin        218            BRCA1                                                              CTX                                      34a     Notch 1
  doxorubicin      489            Smad3, EMT                                                         cisplatin                                27a     BAK-SMAC/DIABLO-XIAP Pathway
  doxorubicin      181a           Bcl-2                                                              cisplatin                                221     BIM/Bcl-2/Bax/Bak
  docetaxel        34a            C22ORF28                                                           docetaxel                                346     SRCIN1
  docetaxel        638            STARD10                                                            doxorubicin                              196b    MAPK signalling pathway, cytokine--cytokine receptor interaction
  docetaxel        125a-3p        BRCA1                                                              doxorubicin                              200a    MAPK signalling pathway, cytokine--cytokine receptor interaction
  doxorubicin      195            Raf-1                                                              doxorubicin                              34a     Notch 1
  docetaxel        139            Notch 1                                                            doxorubicin                              451a    PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes
  docetaxel        27b            ENPP1                                                              doxorubicin                              429     MAPK signalling pathway, cytokine--cytokine receptor interaction
  docetaxel        205            VEGF/FGF2                                                          gemcitabine                              484     CDA/Cyclin-dependent kinase
  doxorubicin      145            MAPK signalling pathway, cytokine--cytokine receptor interaction   lapatinib                                16      CCNJ/FUBP1
  doxorubicin      370            MAPK signalling pathway, cytokine--cytokine receptor interaction   tamoxifen                                148a    ALCAM
  doxorubicin      576-3p         MAPK signalling pathway, cytokine--cytokine receptor interaction   tamoxifen                                152     ALCAM
  doxorubicin      760            MAPK signalling pathway, cytokine--cytokine receptor interaction   tamoxifen                                Let-7   MAPK/Akt, ER-α36
  doxorubicin      765            MAPK signalling pathway, cytokine--cytokine receptor interaction   tamoxifen                                155     SOCS6-STAT3 signalling pathway
  doxorubicin      125b-1         MAPK signalling pathway, cytokine--cytokine receptor interaction   taxol + doxorubicin + cyclophosphamide   128     Bax
  doxorubicin      Let-7a         MAPK signalling pathway, cytokine--cytokine receptor interaction   trastuzumab                              16      CCNJ/FUBP1
  doxorubicin      130a-3p        PTEN/Akt, MAPK, RhoA, FOXO3 and PDCD4 genes                                                                         
  doxorubicin      205            VEGF/FGF2                                                                                                           
  epirubicin       Let-7          HMGA2                                                                                                               
  fulvestrant      214            UCP2/PI3K-Akt-mTOR pathway                                                                                          
  mitoxantrone     326            MRP-1                                                                                                               
  Paclitaxel       24             ABCB9                                                                                                               
  Paclitaxel       34a            Notch 1                                                                                                             
  Paclitaxel       100            mTOR                                                                                                                
  PiB              200            Pin1                                                                                                                
  tamoxifen        342            Cyclin B1, p53, BRCA1 gene                                                                                          
  tamoxifen        27b-3p         NR5A2/CREB1                                                                                                         
  tamoxifen        378a-3p        GOLT1A                                                                                                              
  tamoxifen        320a           ARPP-19/ERRᵧ, c-Myc, Cyclin D1                                                                                      
  tamoxifen        21             Estrogen-dependent cellular functions                                                                               
  tamoxifen        181a           Estrogen-dependent cellular functions                                                                               
  tamoxifen        181b           Estrogen-dependent cellular functions                                                                               
  tamoxifen        200c           Estrogen-dependent cellular functions                                                                               
  tamoxifen        23b            Estrogen-dependent cellular functions                                                                               
  tamoxifen        26a            Estrogen-dependent cellular functions                                                                               
  tamoxifen        26b            Estrogen-dependent cellular functions                                                                               
  tamoxifen        27b            Estrogen-dependent cellular functions                                                                               
  tamoxifen        1254           CCAR1                                                                                                               
  tamoxifen        214            UCP2/PI3K-Akt-mTOR pathway                                                                                          
  VP-16            326            MRP-1                                                                                                               

Anthracyclin: epirubicin/doxorubicin.

[^1]: These authors have contributed equally.
